COMMUNIQUÉS West-GlobeNewswire

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2017

13/07/2017 - 15:14

Communiqué de presse Villepinte, le 13 juillet 2017 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l' [...]

Merus annonce les résultats financiers du premier trimestre 2017 et les résultats d'exploitation de mi-exercice

13/07/2017 - 14:22

Le bilan a été renforcé par un paiement initial de 120 millions de dollars et un achat de 80 millions de dollars d'actions auprès d'Incyte Corporation pour une collaboration de recherche stratégique mondiale en vue de [...]

Crown Bioscience Expands its Life Science Portfolio

13/07/2017 - 14:00

SANTA CLARA, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company [...]

IBA SA : IBA - NOTIFICATION DE TRANSPARENCE

13/07/2017 - 09:25

IBA - NOTIFICATION DE TRANSPARENCE Louvain-la-Neuve, Belgique, 11 juillet 2017, 17h40 - IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce [...]

IBA SA : IBA - TRANSPARENCY NOTIFICATION

13/07/2017 - 09:25

IBA - TRANSPARENCY NOTIFICATION Louvain-la-Neuve, Belgium, July 11, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that [...]

Weifa ASA: Record second-quarter revenues driven by pain and cough & cold

13/07/2017 - 07:30

Oslo, 13 July 2017 Record second-quarter revenues of NOK 98.6 million (NOK 95.3 million) All-organic growth of 3.4% Second-quarter adjusted EBITDA of NOK 22.1 million (NOK 18.6 million) Adjusted EBITDA margin of 22.5% ( [...]

Vistin Pharma ASA : agreement to sell Opioids and CMO business - extended announcement

13/07/2017 - 07:30

Oslo, Norway, 13 July 2017 Reference is made to the stock exchange announcement on 11 July relating to the sale of Vistin Pharma ASA's ("Vistin Pharma" or "Company") opioids and tablet manufacturing business (CMO) ( [...]

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

12/07/2017 - 23:20

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is under FDA priority review; if [...]

Sanofi: Availability of the Pre-quarterly Results Communication

12/07/2017 - 22:30

Availability of the Pre-quarterly Results Communication Paris, France - July 12, 2017 - Sanofi announced today that its Pre-Quarterly Results Communication document is available on the "Investors" page of the company's [...]

Sanofi: Pre-quarterly Results Communication

12/07/2017 - 22:30

Paris, July 12, 2017 Pre-quarterly Results Communication Sanofi (EURONEXT: SAN and NYSE: SNY) has compiled the following items for consideration to assist in the financial modeling of the company's Q2 2017 results. [...]

Sanofi : Mise en ligne du document «Pre-quarterly Results Communication »

12/07/2017 - 22:30

Mise en ligne du document «Pre-quarterly Results Communication » Paris, France - Le 12 juillet 2017 - Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « [...]

SPINEWAY : S1 2017 Bilan semestriel du contrat de liquidité

12/07/2017 - 20:51

Communiqué de Presse Ecully, 12 juillet 2017 BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE Au titre du contrat de liquidité confié par la société SPINEWAY à PORTZAMPARC Société de Bourse, à la date du 30 juin 2017 , les [...]

SPINEWAY:Liquidity contract half-yearly report

12/07/2017 - 20:51

Press release Ecully, 12 July 2017 LIQUIDITY CONTRACT HALF-YEARLY REPORT Regarding liquidity contract granted by SPINEWAY to PORTZAMPARC, the liquidity account held the following assets on 30th June 2017: 20 570 shares [...]

AB Science annonce l'obtention d'un nouveau brevet européen protégeant jusqu'en 2033 l'utilisation du masitinib chez les patients atteints du cancer du pancréas

12/07/2017 - 17:56

Paris, 12 juillet 2017, 17h45 AB Science annonce l'obtention d'un nouveau brevet européen protégeant jusqu'en 2033 l'utilisation du masitinib chez les patients atteints du cancer du pancréas et présentant une douleur [...]

AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients

12/07/2017 - 17:56

Paris, 12 July 2017, 5.45pm AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients with pain until 2033 Recruitment target before possible resampling of [...]

AB Science annonce l'obtention d'un nouveau brevet européen protégeant jusqu'en 2033 l'utilisation du masitinib chez les patients atteints du cancer du pancréas

12/07/2017 - 17:46

Paris, 12 juillet 2017, 17h45 AB Science annonce l'obtention d'un nouveau brevet européen protégeant jusqu'en 2033 l'utilisation du masitinib chez les patients atteints du cancer du pancréas et présentant une douleur [...]

AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients

12/07/2017 - 17:46

Paris, 12 July 2017, 5.45pm AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients with pain until 2033 Recruitment target before possible resampling of [...]

FIT Biotech Oy: FIT Biotech Receives EUR 644,868 Payment from European HIV Vaccine Alliance (EHVA)

12/07/2017 - 15:00

FIT Biotech Oy Company release 12 July, 2017 at 4:00 PM EET FIT Biotech Receives EUR 644,868 Payment from European HIV Vaccine Alliance (EHVA) FIT Biotech Oy ("Company") has received today a EUR 644,868 payment from its [...]

RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease

12/07/2017 - 14:00

The second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn's disease (MAP US study) is planned to be held in late July 2017 and will assess the safety and efficacy of [...]